IMS Health, Sep 2011, Pages: 43
The PharmaceuticalPricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise
Decision Resources, Inc., May 2008, Pages: 39
of postmarketing price cuts are in place to curb pharmaceutical expenditures?
- The reimbursementprices of new drugs in Japan are determined by confi dential negotiations between the manufacturer and the Japanese
Business Insights, Nov 2007, Pages: 143
for drugs/services in Japan
-Classification for price premium (Japanese healthcare system)
-Future pricing scenarios in JapanPharmaceuticalPricing and Reimbursement: Strategies for Market Access Across
Business Insights, April 2005, Pages: 240
likely pricing scenario prevailing in Japan will involve a continuation of the current reimbursement reform led by biennial price-cutting. By weighting the cuts against generic
and 'me-too' products
GBI Research, Nov 2011, Pages: 68
and Reimbursement in Europe, European Counties, the US, Japan, Total Healthcare Expenditure vs Out-of-Pocket Expenditure in European Countries, 2009
Figure 11: Pricing and Reimbursement in Europe, Pharmaceutical
IMS Health, Jan 2007, Pages: 380
-Japan
-Netherlands
-New Zealand
-Norway
-Poland
-Portugal
-South Africa
-Spain
-Sweden
-Switzerland
-United Kingdom
-United States of America IMS PharmaceuticalPharmaceuticalPricing and Reimbursement
Business Insights, Nov 2009, Pages: 145
and reimbursement systems operating across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK)
- Evaluate current trends in order to identify future pricing and reimbursement opportunities
GBI Research, Feb 2010, Pages: 83
of ReimbursementPrices in Japan, 1992–2008
Table 11: Sales in Pharmaceutical Industry, China, $bn, 1998–2008
Table 12: Increase in the Per Capita Expenditure for Medical Services in the Urban and Rural Households
Decision Resources, Inc., Aug 2011
Disorders
Other Disorders
Japan
General Environment
Health Insurance
PharmaceuticalReimbursement
Cost Containment
Musculoskeletal Disorders
Gastrointestinal Disorders
Other Disorders
Decision Resources, Inc., Dec 2009, Pages: 58
for the Pharmaceutical Industry
Tables
1. Ex-Manufacturer Prices of Select Targeted Cancer Therapies in Europe and Japan as a Percentage of U.S. Prices, 2008
2. U.S. Commercial Health Plans’ Formulary Positioning
Decision Resources, Inc., May 2011
For the international pharmaceutical industry, 2011 began as 2010 ended, with governments in the United States, Europe, and Japan looking to cut costs in the short term and to restructure healthcare
Decision Resources, Inc., Oct 2011
Allergies
United Kingdom
General Environment
- Health Insurance Coverage
- PharmaceuticalPricing and Reimbursement
- Cost Containment
Asthma
COPD
Allergies
Japan
General Environment
IMS Health, Dec 2007, Pages: 126
of pricing and reimbursement systems. Categorised country by country, each chapter covers:
Facts and Figures
- Demographics
- Economics
- Healthcare
- Pharmaceuticals
Healthcare System
Pharmaceutical
Business Insights, Oct 2010, Pages: 110
in JapanPricing and reimbursement in France
Pricing and reimbursement in Germany
IQWiG
Pricing and reimbursement in Italy
Risk-sharing schemes
Pricing and reimbursement in Spain
Internal reference
Decision Resources, Inc., Nov 2006, Pages: 52
Prescribing 43
Japan 43
PharmaceuticalPricing and Reimbursement 43
Prospective Payment 44
Unavailability of Gold-Standard Therapies 45
Off-Label Prescribing 47
Outlook and Implications for the Pharmaceutical
Decision Resources, Inc., July 2010, Pages: 40
Is the world’s second largest pharmaceutical market primed for new growth? Although Japan is the second largest pharmaceutical market in the world, regulatory hurdles, a difficult pricing
Just Pharma Reports, Nov 2010, Pages: 66
in the world.
Currently ranked fourth in Asia-Pacific after Japan, China and India, but ahead of Australia drug sales at manufacturer selling prices are the equivalent of USD 11 billion. If you consider
Decision Resources, Inc., March 2011, Pages: 70
in this report:
- The United States has the highest overall prescription drug prices of any of the major pharmaceutical markets. How do the prices of metabolic disease therapies in Europe and Japan compare
Decision Resources, Inc., May 2010, Pages: 37
the pharmaceutical industry in Japan: biennial price revision based on market prices; price cuts for long-listed drugs; repricing in response to market expansion; introduction of a price premium to promote the launch
Arrowhead Publishers, March 2006, Pages: 209
-Synthelabo Merger
Case Study: Japan: Daiichi and Sankyo Merger
Case Study: Supplementary Protection Certificates and Data Exclusivity in Europe
5 An Introduction to Pricing and Reimbursement
5.1 The Basics
